ACP-204 for Alzheimer's Disease

Recruiting in Palo Alto (17 mi)

+33 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 3

Waitlist Available

Sponsor: ACADIA Pharmaceuticals Inc.

No Placebo Group

Pivotal Trial (Near Approval)

Prior Safety Data

Trial Summary

What is the purpose of this trial?This 52-week, open-label extension study is to evaluate the long-term safety and tolerability of ACP-204 in subjects with ADP.

Eligibility Criteria

This trial is for adults aged 55 to 95 with Alzheimer's Disease Psychosis who finished the ACP-204-006 study. Participants need a caregiver, must not be pregnant or breastfeeding, and should not have any severe medical conditions that could affect their safety or ability to complete the study.

Inclusion Criteria

Subjects are able to complete all study visits with a study partner/caregiver

Signed inform consent form with a caregiver or legal representative

I am between 55 and 95 years old. If female, I cannot have children. If male, I will use contraception.

+2 more

Exclusion Criteria

I am not pregnant or breastfeeding.

I do not have any unstable health conditions besides Alzheimer's Disease.

I need to take a medication that is not allowed in this study.

+2 more

Participant Groups

The trial is testing the long-term safety and effectiveness of a drug called ACP-204 over a period of one year in patients with Alzheimer's Disease Psychosis who have already completed an initial study.

1Treatment groups

Experimental Treatment

Group I: ACP-204Experimental Treatment1 Intervention

ACP-204 30mg or 60mg